AR095615A1 - Purificación de anticuerpos y monitoreo de pureza - Google Patents

Purificación de anticuerpos y monitoreo de pureza

Info

Publication number
AR095615A1
AR095615A1 ARP140101240A ARP140101240A AR095615A1 AR 095615 A1 AR095615 A1 AR 095615A1 AR P140101240 A ARP140101240 A AR P140101240A AR P140101240 A ARP140101240 A AR P140101240A AR 095615 A1 AR095615 A1 AR 095615A1
Authority
AR
Argentina
Prior art keywords
purification
proteins
production
impurities
processes
Prior art date
Application number
ARP140101240A
Other languages
English (en)
Spanish (es)
Inventor
Binh Do Hoa
F Lee Geoffrey
D Davin Steven
F Garcia-Martinez Leon
W Ojala Ethan
Young Mark
Latham John
S Allison Daniel
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of AR095615A1 publication Critical patent/AR095615A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Water Supply & Treatment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP140101240A 2013-03-15 2014-03-17 Purificación de anticuerpos y monitoreo de pureza AR095615A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792935P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095615A1 true AR095615A1 (es) 2015-10-28

Family

ID=51538079

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101240A AR095615A1 (es) 2013-03-15 2014-03-17 Purificación de anticuerpos y monitoreo de pureza

Country Status (8)

Country Link
US (3) US9518082B2 (https=)
EP (2) EP2970865B1 (https=)
JP (1) JP6472786B2 (https=)
AR (1) AR095615A1 (https=)
CA (1) CA2905531C (https=)
ES (1) ES2834113T3 (https=)
TW (2) TWI670279B (https=)
WO (1) WO2014145744A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI670279B (zh) * 2013-03-15 2019-09-01 Alder Biopharmaceuticals, Inc. 抗體純化及純度監測
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2016070062A2 (en) * 2014-10-31 2016-05-06 Genentech, Inc. Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
DK3334747T5 (da) 2015-08-13 2024-10-07 Amgen Inc Ladet dybdefiltrering af antigenbindende proteiner
US11242518B2 (en) 2015-09-04 2022-02-08 QIAGEN Sciences, LLP Methods for co-isolation of nucleic acids and proteins
WO2017153974A1 (en) * 2016-03-07 2017-09-14 Caladrius Biosciences, Inc. A closed system for labelling and selecting live cells
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
CN106293544B (zh) * 2016-08-29 2020-06-30 成都科鸿达科技有限公司 一种高效大规模系统的ltl模型检测方法
CN106371765B (zh) * 2016-08-29 2020-09-18 成都科鸿达科技有限公司 一种高效大规模系统的ltl模型检测去内存抖动的方法
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
JP6829357B2 (ja) * 2017-03-17 2021-02-10 住友ベークライト株式会社 抗体の糖鎖検出法
CN107033236B (zh) * 2017-05-05 2021-03-23 浙江大学 一种从酵母发酵液中分离人血白蛋白的混合模式层析方法
CN107254502A (zh) * 2017-07-26 2017-10-17 兰州名德农牧科技有限公司 一种动物蛋白酶制备羊胎盘肽的方法
MA49962A (fr) 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
CN120943884A (zh) * 2018-03-27 2025-11-14 百时美施贵宝公司 使用紫外线信号实时监测滴度
EP3781941B1 (en) 2018-04-20 2026-01-14 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-tnf antibody compositions
EP3784796A1 (en) 2018-04-24 2021-03-03 Qiagen Sciences, LLC Nucleic acid isolation and inhibitor removal from complex samples
GB201806752D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method in bioprocess system
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US11187707B2 (en) 2019-01-30 2021-11-30 Regeneron Pharmaceuticals, Inc. Method of characterization of visible and/or sub-visible particles in biologics
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
CA3151967A1 (en) * 2019-09-23 2021-04-01 Marina Hincapie Product quality attribute measurement
CN111239408B (zh) * 2020-01-19 2023-02-10 深圳格道糖生物技术有限公司 特定凝集素组合在构建基于唾液糖蛋白糖链鉴别肝纤维化的测试工具方面的应用
WO2021150996A1 (en) * 2020-01-24 2021-07-29 Amgen Inc. Methods for harvesting biomolecules
JP2020099909A (ja) * 2020-03-17 2020-07-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 処理方法、生産方法およびハイドロキシアパタイト充填剤
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
CN111579777B (zh) * 2020-05-29 2024-02-02 江苏省苏微微生物研究有限公司 一种以大粒径凝胶为载体的亲和介质及其应用
CA3202531A1 (en) * 2020-11-18 2022-05-27 Modernatx, Inc. Ribonucleic acid purification
GB202105559D0 (en) * 2021-04-19 2021-06-02 Cytiva Bioprocess R & D Ab Method of clarifying a crude protein solution
CN117279929A (zh) * 2021-05-10 2023-12-22 凯奥目生物科学株式会社 抗体组合物的纯化方法
CN113416243B (zh) * 2021-08-23 2021-12-10 上海盛迪医药有限公司 一种纯化抗体的方法
CN114279968B (zh) * 2021-12-28 2024-09-20 中国科学院长春应用化学研究所 一种电化学-双偏振干涉光电检测池
CN116159340A (zh) * 2022-12-16 2023-05-26 浙江大学 一种用于体积排阻色谱法的缓冲液
WO2025155751A1 (en) * 2024-01-17 2025-07-24 Nutcracker Therapeutics, Inc. Improved method for isolating and characterizing proteins
CN118006716B (zh) * 2024-03-15 2024-09-10 通化安睿特生物制药股份有限公司 制备高表达且低o-糖基化水平的重组人白蛋白的方法
CN119000228B (zh) * 2024-08-26 2025-02-28 西南大学 蛋白质组学样品前处理清洗装置
CN119832975A (zh) * 2024-12-24 2025-04-15 上海药明生物技术有限公司 一种蛋白质共处方制剂的稳定性预测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6730499B1 (en) 1998-07-03 2004-05-04 Research Corporation Technologies, Inc. Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US20030091976A1 (en) 2001-11-14 2003-05-15 Ciphergen Biosystems, Inc. Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
JPWO2004087761A1 (ja) * 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
WO2004090549A1 (en) * 2003-04-11 2004-10-21 Novozymes A/S Method of screening for secreted glycosylated polypeptides
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP1869065B1 (en) * 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
EP3539981A1 (en) * 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
MX2009007139A (es) * 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
CA2887752C (en) * 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
AU2008291358A1 (en) * 2007-08-31 2009-03-05 F. Hoffmann-La Roche Ag Glycosylation profile analysis
EP2490780A4 (en) * 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
SG10201503899SA (en) * 2010-05-18 2015-06-29 Abbvie Inc Apparatus And Process Of Purification Of Proteins
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
CN103827134A (zh) * 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
US10150968B2 (en) 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
SG10201609752YA (en) * 2011-08-19 2017-01-27 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
WO2013176754A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
TWI670279B (zh) * 2013-03-15 2019-09-01 Alder Biopharmaceuticals, Inc. 抗體純化及純度監測

Also Published As

Publication number Publication date
US10533045B2 (en) 2020-01-14
WO2014145744A1 (en) 2014-09-18
EP2970865A1 (en) 2016-01-20
US20140288272A1 (en) 2014-09-25
ES2834113T3 (es) 2021-06-16
US20170137500A1 (en) 2017-05-18
CA2905531A1 (en) 2014-09-18
US12590142B2 (en) 2026-03-31
JP6472786B2 (ja) 2019-02-20
US20200223913A1 (en) 2020-07-16
TWI670279B (zh) 2019-09-01
EP2970865B1 (en) 2020-09-02
US9518082B2 (en) 2016-12-13
EP3754012A1 (en) 2020-12-23
JP2016512848A (ja) 2016-05-09
TW201514195A (zh) 2015-04-16
CA2905531C (en) 2023-01-03
TW201940691A (zh) 2019-10-16
EP2970865A4 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
AR095615A1 (es) Purificación de anticuerpos y monitoreo de pureza
WO2015120287A3 (en) Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids
MX366647B (es) Cambio de temperatura para una expresión con mayor rendimiento de polipéptidos en levaduras y otras células transformadas.
WO2015004241A3 (en) Multiple proteases deficient filamentous fungal cells and methods of use thereof
MX381995B (es) Métodos para la producción de polipéptidos procesados proteolíticamente.
BR112014020694A2 (pt) proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
EP3358000A3 (en) Protease deficient filamentous fungal cells and methods of use thereof
IL240689B (en) Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
WO2013060867A3 (en) Production of heterodimeric proteins
WO2016196315A3 (en) Cell culture methods and systems
HK1211981A1 (en) Methods to control protein heterogeneity
ZA201506478B (en) Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
HRP20190484T1 (hr) Pripravci stanične kulture i postupci proizvodnje polipeptida
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
WO2014151878A3 (en) Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
SG178870A1 (en) Processes for producing silk dope
EP3083966A4 (en) Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling
EP2947143A4 (en) RECOMBINANT CELL AND METHOD FOR PREPARING 1,4-BANDALIUM
MX390701B (es) Manufactura de proteína.
EP2935581A4 (en) EXPRESSION VECTORS FOR THE PRODUCTION OF RECOMBINANT PROTEINS IN MAMMALIAN CELLS
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
EP3839055A3 (en) Yeast promoters for protein expression
EP3448884C0 (en) Engineered mammalian cells for production of recombinant proteins
AR090340A1 (es) Operaciones de cosecha mejoradas para proteinas recombinadas

Legal Events

Date Code Title Description
FB Suspension of granting procedure